230 related articles for article (PubMed ID: 23971897)
1. Diagnosis of acromegaly: state of the art.
Kannan S; Kennedy L
Expert Opin Med Diagn; 2013 Sep; 7(5):443-53. PubMed ID: 23971897
[TBL] [Abstract][Full Text] [Related]
2. Hormonal diagnosis of GH hypersecretory states.
Grottoli S; Gasco V; Ragazzoni F; Ghigo E
J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
[TBL] [Abstract][Full Text] [Related]
3. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
4. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
5. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
6. Current concepts in the biochemical assessment of the patient with acromegaly.
Freda PU
Growth Horm IGF Res; 2003 Aug; 13(4):171-84. PubMed ID: 12914750
[TBL] [Abstract][Full Text] [Related]
7. Are there alternative tests for diagnosis of acromegaly?
Popovic V
J Endocrinol Invest; 2005; 28(11 Suppl International):73-4. PubMed ID: 16625850
[TBL] [Abstract][Full Text] [Related]
8. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
9. Biochemical markers of acromegaly: GH vs. IGF-I.
Barkan AL
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S97-100. PubMed ID: 15135787
[TBL] [Abstract][Full Text] [Related]
10. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.
Dimaraki EV; Jaffe CA; DeMott-Friberg R; Chandler WF; Barkan AL
J Clin Endocrinol Metab; 2002 Aug; 87(8):3537-42. PubMed ID: 12161471
[TBL] [Abstract][Full Text] [Related]
11. Gender and age in the biochemical assessment of cure of acromegaly.
Freda PU; Landman RE; Sundeen RE; Post KD
Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
[TBL] [Abstract][Full Text] [Related]
12. Current diagnostic guidelines for biochemical diagnosis of acromegaly.
Ferone D; Resmini E; Bocca L; Giusti M; Barreca A; Minuto F
Minerva Endocrinol; 2004 Dec; 29(4):207-23. PubMed ID: 15765030
[TBL] [Abstract][Full Text] [Related]
13. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
[TBL] [Abstract][Full Text] [Related]
14. IGF-I and mortality in patients with acromegaly.
Strasburger CJ
J Endocrinol Invest; 2005; 28(11 Suppl International):78-80. PubMed ID: 16625852
[TBL] [Abstract][Full Text] [Related]
15. Biochemical evidence supporting the Cortina criteria.
von Werder K
J Endocrinol Invest; 2005; 28(11 Suppl International):81-3. PubMed ID: 16625853
[TBL] [Abstract][Full Text] [Related]
16. Laboratory investigation of acromegaly: is basal or random GH > 0.4 µg/L in the presence of normal serum IGF-1 an important result?
Rosario PW; Calsolari MR
Arch Endocrinol Metab; 2015 Feb; 59(1):54-8. PubMed ID: 25926115
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of measurements of insulin-like growth factor 1.
Clemmons DR
Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):436-46. PubMed ID: 16932333
[TBL] [Abstract][Full Text] [Related]
18. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
[TBL] [Abstract][Full Text] [Related]
19. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Bastemir M; Akin F; Yaylali GF
Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
[TBL] [Abstract][Full Text] [Related]
20. [The place of insulin-like growth factor I in the diagnosis of acromegaly].
Dohán O; Góth M; Szabolcs I; Kovács L; Kovács Z; Szilágyi G
Orv Hetil; 1993 Oct; 134(42):2301-3. PubMed ID: 8233444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
